RYALTRIS
Peakolopatadine hydrochloride and mometasone furoate
NDANASALSPRAY, METERED
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYALTRIS is a fixed-dose combination nasal spray containing olopatadine (a selective H1 receptor antagonist) and mometasone furoate (an intranasal corticosteroid). It is indicated for allergic rhinitis and represents a dual-mechanism approach combining antihistamine and anti-inflammatory activity. The combination targets both immediate allergic response (olopatadine) and underlying inflammatory pathways (mometasone).
$0.001BPart D
Peak12.9 years to LOEEarly-stage peak revenue trajectory with low current Part D spending suggests significant market penetration opportunity ahead; brand team likely expanding in size and scope.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RYALTRIS roles are not currently tracked in the linked job database, but as an early-peak product with 13 years of patent protection and no competitive threats, roles are expected to include brand management, medical affairs, market access, and sales support. Career growth potential is tied to successful market share capture in allergic rhinitis and possible line extension strategies.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.